Cargando…

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis

PURPOSE: The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ha-young, Shin, Sang Joon, Kim, Hyo Song, Hong, Soo Jung, Han, Jung Woo, Lim, Seung Taek, Roh, Jae Kyung, Rha, Sun Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322200/ https://www.ncbi.nlm.nih.gov/pubmed/22500160 http://dx.doi.org/10.4143/crt.2012.44.1.43

Ejemplares similares

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
por: Choi, Yunjung, et al.
Publicado: (2018)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
por: Lim, Sun Min, et al.
Publicado: (2015)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
por: Kim, Sang Kyum, et al.
Publicado: (2021)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
por: Tanaka, Kazuhiro, et al.
Publicado: (2016)

Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
por: Kim, Chan, et al.
Publicado: (2016)

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
por: Hara, Hitomi, et al.
Publicado: (2019)

Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
por: Pan, Minggui, et al.
Publicado: (2021)

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016)

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)

Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel
por: Joung, Jae Young, et al.
Publicado: (2008)

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors
por: Yoon, Jong Hyung, et al.
Publicado: (2014)

A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
por: Jeon, Ye Won, et al.
Publicado: (2017)

Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
por: Harrer, Dennis Christoph, et al.
Publicado: (2021)

Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review
por: Conry, Robert M
Publicado: (2014)

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis
por: Takahashi, Masanobu, et al.
Publicado: (2017)

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
por: Kim, Jung Hoon, et al.
Publicado: (2018)

Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics
por: Lee, Yurimi, et al.
Publicado: (2022)

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
por: Jones, Robin L., et al.
Publicado: (2019)

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2023)

Clinical Outcomes of Surgical Treatment for Primary Chest Wall Soft Tissue Sarcoma
por: Yoon, Seung Hwan, et al.
Publicado: (2019)

Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
por: Kim, Hyo Song, et al.
Publicado: (2019)

Role of Matrix Metalloproteinase (MMP) 2 and MMP-9 in Soft Tissue Sarcoma
por: Yang, Hyun Kee, et al.
Publicado: (2014)

Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021)

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
por: Seddon, Beatrice, et al.
Publicado: (2017)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
por: Lim, Hyun-Kyung, et al.
Publicado: (2016)

A Case of Alveolar Soft Part Sarcoma of the Pleura
por: Ju, Hyeong Uk, et al.
Publicado: (2013)

Metastatic follicular dendritic cell sarcoma treated with gemcitabine plus docetaxel with an outstanding survival: A case report and review of literature
por: Esmati, Ebrahim, et al.
Publicado: (2020)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

Pulmonary Metastases of Alveolar Soft-Part Sarcoma: CT Findings in Three Patients
por: Choi, Joon-Il, et al.
Publicado: (2000)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
por: Lee, Choong-kun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_aek7bic2eqnstfjae4uae4bm25